We are live on ! Find out more
OASM

Oasmia Pharmaceutical AB
OASM

Delisted

OASM was delisted on the 21st of August, 2019.

Back to rankings

6 hedge funds and large institutions have $226K invested in Oasmia Pharmaceutical AB in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

50% more funds holding

Funds holding: 4 → 6 (+2)

11% less capital invested

Capital invested by funds: $253K → $226K (-$27K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$17.8K
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$13K
3
Morgan Stanley
Morgan Stanley
New York
+$1

Top Sellers

Rank Fund Capital Flow
1
OMC
Old Mission Capital
Illinois
-$18K
2
UBS Group
UBS Group
Switzerland
-$1.54K

OASM Hedge Fund Activity: Q4 2017 in Review

6 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q4 2017, worth a combined $226K — down 11% from $253K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new OASM positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $17.8K. The largest seller was Old Mission Capital, exiting entirely with an estimated $18K sold.

  • 6 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q4 2017, up from 4 in Q3 2017.
  • Funds reported $226K of Oasmia Pharmaceutical AB stock for Q4 2017, down 11% quarter-over-quarter.
  • 3 funds opened new Oasmia Pharmaceutical AB positions in Q4 2017 and 1 closed out, a net change of +2 holders.
  • The largest Oasmia Pharmaceutical AB buyer in Q4 2017 was Citadel Advisors, an estimated $17.8K added.
  • The largest Oasmia Pharmaceutical AB seller in Q4 2017 was Old Mission Capital, an estimated $18K sold.

Based on aggregated 13F filings for Q4 2017.